Lemaitre Dan 4
4 · GLOBUS MEDICAL INC · Filed May 14, 2024
Insider Transaction Report
Form 4
Lemaitre Dan
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy Class A Common Stock)
2024-05-10−17,500→ 0 totalExercise: $43.58Exp: 2029-01-22→ Class A Common Stock (17,500 underlying) - Sale
Class A Common Stock
2024-05-10$64.61/sh−63,300$4,090,022→ 0 total - Exercise/Conversion
Class A Common Stock
2024-05-10$43.77/sh+17,500$765,975→ 28,300 total - Exercise/Conversion
Class A Common Stock
2024-05-10$53.27/sh+17,500$932,225→ 63,300 total - Exercise/Conversion
Stock Option (Right to Buy Class A Common Stock)
2024-05-10−17,500→ 0 totalExercise: $53.27Exp: 2030-01-22→ Class A Common Stock (17,500 underlying) - Exercise/Conversion
Class A Common Stock
2024-05-10$43.58/sh+17,500$762,650→ 45,800 total - Exercise/Conversion
Stock Option (Right to Buy Class A Common Stock)
2024-05-10−17,500→ 0 totalExercise: $43.77Exp: 2028-01-22→ Class A Common Stock (17,500 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.80 to $64.68, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]These options were granted on January 22, 2018 and are fully vested.
- [F3]These options were granted on January 22, 2019 and are fully vested.
- [F4]These options were granted on January 22, 2020 and are fully vested.